Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487
In development [GID-TA10437] Expected publication date: TBC
Search results
488 results
-
-
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997
In development [GID-TA10382] Expected publication date: TBC
-
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]
In development [GID-TA10338] Expected publication date: TBC
-
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
In development [GID-TA10151] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492
In development [GID-TA10441] Expected publication date: TBC
-
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]
In development [GID-TA10154] Expected publication date: TBC
-
Renal cell carcinoma - sunitinib [ID1076]
In development [GID-TA10166] Expected publication date: TBC
-
Osteoarthritis - diacerein [ID332]
In development [GID-TAG250] Expected publication date: TBC
-
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172
In development [GID-TA10394] Expected publication date: TBC
-
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
In development [GID-TA10446] Expected publication date: TBC
-
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
In development [GID-TA10404] Expected publication date: TBC
-
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]
In development [GID-TA10445] Expected publication date: TBC
-
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
In development [GID-TA10337] Expected publication date: 19 February 2020
-
Pacritinib for treating myelofibrosis [ID880]
In development [GID-TA10133] Expected publication date: TBC
-
LJ TEST
In development [GID-TA10462] Expected publication date: TBC
-
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288
In development [GID-TA10212] Expected publication date: TBC
-
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
In development [GID-TA10271] Expected publication date: TBC
-
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
In development [GID-TA10575] Expected publication date: TBC
-
Spasticity (after stroke) - botulinum toxin type A [ID768]
In development [GID-TAG499] Expected publication date: TBC
-
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
In development [GID-TA10105] Expected publication date: TBC
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
-
Eculizumab for treating relapsing neuromyelitis optica [ID1271]
In development [GID-TA10469] Expected publication date: 02 September 2020
-
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development [GID-TA10313] Expected publication date: TBC
-
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179
In development [GID-TA10450] Expected publication date: TBC
-
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
In development [GID-TA10561] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published date: 24 May 2019
-
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
In development [GID-TA10254] Expected publication date: TBC
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: TBC
-
Luspatercept for treating beta-thalassaemia ID1554
In development [GID-TA10506] Expected publication date: TBC
-
Kidney transplantation (rejection) - everolimus [ID117]
In development [GID-TAG241] Expected publication date: TBC
-
Selumetinib for treating differentiated thyroid cancer ID1079
In development [GID-TA10207] Expected publication date: TBC
-
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development [GID-TA10249] Expected publication date: TBC
-
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
In development [GID-TA10205] Expected publication date: TBC
-
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development [GID-TA10251] Expected publication date: TBC
-
Eltrombopag for untreated severe aplastic anaemia ID1198
In development [GID-TA10284] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423
In development [GID-TA10330] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228
In development [GID-TA10203] Expected publication date: TBC
-
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]
In development [GID-TA10149] Expected publication date: TBC
-
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)
In development [GID-TA10197] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
In development [GID-TA10168] Expected publication date: TBC
-
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
In development [GID-TA10267] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]
In development [GID-TAG482] Expected publication date: TBC
-
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250
In development [GID-TA10213] Expected publication date: TBC
-
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
In development [GID-TAG507] Expected publication date: TBC
-
Pembrolizumab for previously treated multiple myeloma (ID1139)
In development [GID-TA10193] Expected publication date: TBC
-
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
In development [GID-TAG511] Expected publication date: TBC